R&D Capacity
Strong team consisting of over 200 specialists
R & D expenditure occupies 6%-8% of annual sales
Capable of conducting cross board pre-clinical studies independently for areas like pharmacology, drug analysis, safety evaluation and clinical trials
Focused on new drug discovery, drug delivery system development, DDS platform including Long-acting Extended-Release Microspheres for Injection and Liposome Technology Platform
221 China Patents filed, of which 40 were granted
10 PCT (6 granted)
  R&D Platform
Key technology - Screen and structural modification of novel molecules from natural sources
Key technology - Sustained-release formulation of biodegradable microspheres and pellet
Key technology - Liposome DDS Technology
Therapeutic potency evaluation both in Vivo and in Vitro
Safety evaluation
ADME evaluation both in animal and human body
  R&D Global Collaboration Objectives
In-license drugs are currently at development stage. We focus on specialty drugs in Oncology, Cardiovascular, CNS system,Hepatology, Gastroenterology, Orthopaedics.
Out-license our own proprietary pipeline drugs (New formulation and NCE derived from natural herbs).
Co-develop pre-clinical stage (pharmacology and toxicology) and clinical stage (phase I, II, and III) drug candidates.